Never Run Out Of Buyers To Sell To.

ABL Bio Inc.(Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space,…
Annual Revenue$50M to $100MBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Estimated OwnershipPublicMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.